Abstract 1748P
Background
Obesity has been recognised as one of the main risk factors for non- communicable diseases including cancer. WHO European report suggests that obesity affects 30% of children in Europe. Unhealthy diet is one of the most important determinants of childhood obesity, a condition that has become very prevalent in the south of Europe. Consumption of sugar-sweetened beverages (SSBs) influence childhood obesity and food advertisement is one of the strongest determinants of SSB consumption.
Methods
A multidisciplinary panel of clinicians from the South of Europe (Cyprus, Greece, Italy, Malta, Spain and Portugal) critically reviewed the available legislation and recommendations on SSB advertisements, in native language. The website of relevant national societies (Cardiovascular, Diabetic, Oncology, Paediatric and Stroke) was reviewed. Herein we present the recommendations from Oncology national societies.
Results
The countries in study have national legislations on SSB advertisements following EU directives with Spain having the most comprehensive regulatory framework. None of the oncology societies had recommendations on SSB consumption from children. The Spanish oncology society (SEOM) recognised obesity as risk factor for developing cancer and a close collaboration with the Spanish Association for the study of obesity is suggested. The Portuguese Society of Oncology (SPO) provides general guidance on the role of food and nutrition in cancer development. In Greece and Cyprus sporadic publications from the oncology society (HeSMO) on the preventive role of diet was noticed with no concrete guidance. Italian Oncology society (AIOM) has published on the role of nutritional support for cancer patients but the preventive role of healthy diet on childhood obesity is not available. European society of Medical Oncology links to IARC prevention strategies in the society website.
Conclusions
Recommendations on healthy diet to tackle childhood obesity, including SSB advertisement, from national medical societies in South Europe is fragmented. Oncology societies should join forces with other medical societies to increase awareness of childhood obesity and implement measures to address the phenomenon.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23